Product Datasheet

RelB (phospho Ser552) Polyclonal Antibody

Catalog No: #13569

Package Size: #13569-1 50ul #13569-2 100ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Des	cri	nti	on
Des	UH	μu	OI I

777	
Product Name	RelB (phospho Ser552) Polyclonal Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
	immunogen.
Applications	WB;IHC;IF;ELISA
Species Reactivity	Human,Mouse
Specificity	Phospho-RelB (S552) Polyclonal Antibody detects endogenous levels of RelB protein only when
	phosphorylated at S552.
Immunogen Description	The antiserum was produced against synthesized peptide derived from human RelB around the
	phosphorylation site of Ser552. AA range:530-579
Conjugates	Unconjugated
Other Names	RELB; Transcription factor RelB; I-Rel
Accession No.	Swiss Prot:Q01201GeneID:5971
SDS-PAGE MW	62
Concentration	1 mg/ml
Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage	-20°C/1

Application Details

WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000; IF 1:50-200

Background

caution:Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B.,domain:Both N- and C-terminal domains are required for transcriptional activation.,function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.,induction:By mitogens.,PTM:Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.,similarity:Contains 1 RHD (Rel-like) domain.,subunit:Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p

Note: This product is for in vitro research use only and is not intended for use in humans or animals.					